PTHS: Pelthos Therapeutics Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 3 sales totaling $45K in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2026-10-02 | Greenleaf Peter | Director | $17K | yes |
| 2026-10-02 | Friedberg Ezra M | Director | $12K | yes |
| 2026-10-02 | Pauls Matthew | Director | $17K | yes |
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-11-03 | 13D amendment | Ligand Pharmaceuticals Incorporated | 49.90% | SEC |
Institutional ownership (Q2 2026)
24 institutions reported holding $38.47M of Pelthos Therapeutics Inc. on Form 13F (17 the quarter before). 10 opened a new position and 3 sold out. Shares held by institutions: +49%.
| Largest holders | Shares | Value |
|---|---|---|
| AIGH Capital Management LLC | 329,098 | $9.30M |
| Murchinson Ltd. | 304,302 | $8.60M |
| Ikarian Capital, LLC | 256,598 | $7.25M |
| BOOTHBAY FUND MANAGEMENT, LLC | 101,976 | $2.88M |
| VANGUARD CAPITAL MANAGEMENT LLC | 97,134 | $2.75M |
| CANTOR FITZGERALD, L. P. | 76,246 | $2.15M |
| J. Goldman & Co LP | 38,075 | $1.08M |
| DIADEMA PARTNERS LP | 24,773 | $700K |
| WEXFORD CAPITAL LP | 22,364 | $632K |
| Knott David M Jr | 22,073 | $624K |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.